Myriad Genetics (STU:MYD) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:MYD Myriad Genetics Inc STU:MYD
61 GF Score
Price €4.62
GF Value €13.07
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics 5-Year Yield-on-Cost %?

Myriad Genetics STU:MYD +3.61% 61 5-Year Yield-on-Cost % is 0.00 as of Jul. 31, 2026. GuruFocus rates STU:MYD with a GF Score™ of 61/100 and a GF Value™ of €13.07 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 63 Medical Diagnostics & Research companies, Myriad Genetics ranks worse than 1587300% on this metric.

Myriad Genetics's yield on cost for the quarter that ended in Jun. 2026 was 0.00.


The historical rank and industry rank for Myriad Genetics's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:MYD's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.5
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Myriad Genetics  (STU:MYD) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Myriad Genetics 5-Year Yield-on-Cost % Related Terms


STU:MYD vs FLGT, CSTL, BDSX: 5-Year Yield-on-Cost % Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Myriad Genetics 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's 5-Year Yield-on-Cost % falls into.


STU:MYD
61GF Score
Myriad Genetics Inc STU:MYD
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Myriad Genetics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Myriad Genetics (STU:MYD) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Myriad Genetics and its competitors. According to the industry distribution chart, Myriad Genetics ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry.
Is Myriad Genetics' 5-Year Yield-on-Cost % too high?
Myriad Genetics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Myriad Genetics ranks #999999 out of 63 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Myriad Genetics has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' 5-Year Yield-on-Cost % compare to FLGT and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Myriad Genetics ranks #999999 out of 63 companies for 5-Year Yield-on-Cost %. This places Myriad Genetics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.50, based on 63 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Myriad Genetics and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Myriad Genetics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.07, compared to a current price of €4.62 — trading 64.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Myriad Genetics' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €4.62 is trading 64.7% below its estimated GF Value™ of €13.07. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: €13.07 vs. price of €4.62 (64.7% below fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
61GF Score

Get the complete analysis for STU:MYD

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.62
Price
€13.07
GF Value